ARTICLE SUMMARY:
The past year has shown that clinical diagnostics companies have important roles to play in the explosive field of cancer immunotherapies, which has driven so much of the rebirth of the biopharma industry in the last six years; but extracting value in a timely manner is a challenge.
The surprise upset last August by underdog Merck & Co. against Bristol- Myers Squibb (BMS) in a crucial battle to be first to sell a drug in an important segment of the exploding cancer immunotherapy market was certainly a high-profile win for Merck.
